Table of Contents
A GLP-1 biosimilar freedom to operate study is the difference between a launch calendar built on a headline patent date and one built on the claims that actually block entry. When a mid-size follow-on developer asked where and when it could bring a semaglutide product to market, the answer was not one date — it was four, one per target jurisdiction, each gated by a different mix of compound, formulation and device patents.
The Challenge
A follow-on manufacturer wanted to enter the semaglutide market and treated it, at first, as a single go/no-go decision keyed to ‘when the Ozempic patent expires.’ That framing was the risk. The compound patent’s status differs by country, a thicket of formulation, oral-dosing and injection-device patents sits behind it, and semaglutide is classified as a chemical drug in some jurisdictions and a biologic in others — which changes whether the product enters as a generic or a biosimilar and against which register it must certify.
The stakes made the ambiguity expensive. Entering too early in the wrong market risks an injunction and a written-off launch investment; entering too late forfeits first-mover share in a category where the first few generics in India already undercut the branded price by up to 80%. The client’s board wanted a defensible calendar it could fund against, not a caveated memo.
The client needed a GLP-1 biosimilar freedom to operate read that turned that ambiguity into a sequenced, defensible launch plan across the US, Canada, India and Brazil.
Our Approach
We built the analysis in three passes. First, a molecule-level cliff calendar: pulling the US Orange Book listing for semaglutide (dozens of patents filed 2018–2026, roughly nineteen still active) alongside the corresponding national registers to fix the real expiry per market — Canada in January 2026, India and Brazil in March 2026, and the US extended to roughly 2032.
Second, a claim-by-claim FTO read of the patents live in each market, separating the expired compound claims from the formulation, dosing and device claims that survive them. Third, a regulatory-pathway overlay, because a chemical-drug classification (Canada) and a biologic classification (India, Brazil) route the same molecule through different approval regimes and different exclusivity risks.
- Orange Book and national-register pull with active-vs-expired status per patent
- Independent claim charting against the client’s specific formulation and delivery device
- Settlement-landscape review of Novo Nordisk’s US ANDA agreements to bound realistic US entry
- Design-around screen on oral delivery, dosing regimen and pen mechanism
What the Research Found
The markets did not line up. Canada, India and Brazil were open or opening in 2026 on the compound patent, but each still carried live device and formulation claims the client’s presentation would have infringed as designed. The US, by contrast, was closed on the molecule until about 2032 regardless of design — and Novo Nordisk’s chain of ANDA settlements with Alvogen, Sun Pharma, Dr. Reddy’s, Mylan, Zydus and Apotex showed agreed entry dates clustering there rather than an open field.
The device and oral-formulation claims, however, were narrower than the client assumed. Three concrete design-around routes — a clean-sheet auto-injector, an alternative absorption-enhancer chemistry, and a dosing schedule outside the claimed regimen — cleared the surviving claims in the near-term markets.
Timing the US window mattered as much as clearing it. Rather than read the 2032 exposure as a wall to be litigated, we treated Novo Nordisk’s settled ANDA dates as market intelligence: they revealed the entry dates the originator had already conceded to better-capitalised filers, letting the client set a realistic US target instead of gambling on an early Paragraph IV fight it was not resourced to win.
The Outcome
The client replaced a single go/no-go with a phased plan: enter Canada, India and Brazil in 2026 using a redesigned device and formulation that cleared the live claims, and hold the US for a ~2032 window aligned with the settled ANDA dates rather than risking early litigation. The FTO map also became the design brief — engineering knew exactly which claims to steer around before tooling, not after.
The phased plan also reshaped how the client spent its development budget. Capital that would have gone into a premature, litigation-exposed US filing was redirected into the redesigned device and formulation that unlocked three 2026 markets — bringing forward real revenue by years while keeping the larger US prize on a defensible timeline. The FTO study, in other words, paid for itself twice: once in avoided injunctions and once in accelerated cash flow.
What This Means for Similar Matters
The recurring lesson of a GLP-1 biosimilar freedom to operate study is that the compound-patent date is the least useful number in the file. Expiry timing sets the earliest possible entry; the formulation and device claims decide whether the client’s actual product can take it. Sequencing markets to their real cliffs — and designing around the surviving claims up front — turns a blocked launch into a staged one.
Reading the Regulatory-Pathway Split
The classification difference did more than change paperwork. In Canada, where semaglutide is treated as a chemical drug, a follow-on could pursue a conventional generic pathway once the January 2026 compound expiry passed — provided it cleared the surviving device and formulation claims. In India and Brazil, the biologic classification routed the same molecule through a biosimilar comparability exercise, adding development time but also a different, and in places thinner, patent estate to clear.
We mapped each market’s pathway against its patent position so the client could see the true lead time per launch, not just the expiry date. A market that is ‘open’ on the compound patent but requires an 18-month biosimilar comparability programme is not open on the same day as one that accepts an abbreviated chemical-drug filing.
Turning the FTO Map into a Design Brief
The most durable output was not the calendar but the claim charts. By isolating exactly which independent claims survived in each market, the study told the client’s engineers which features to steer around before they committed to tooling. Three routes carried the plan:
- A clean-sheet auto-injector that avoided the specific pen-mechanism claims still live in the near-term markets
- An alternative absorption-enhancer chemistry for the oral line, sidestepping the narrow but dense formulation claims
- A dosing schedule deliberately positioned outside the claimed titration regimen
Because the design constraints were known at the concept stage, the client avoided the most common and costly FTO failure: discovering a blocking claim after the device is frozen, when a redesign means months lost and capital spent twice.
Data Sources
The market and patent data referenced above comes from:
- mLex — Semaglutide patent expiry global split — Country-by-country expiry (Canada Jan 2026, India/Brazil Mar 2026, US ~2032) and regulatory classification split
- FDA — Semaglutide shortage resolution (Foley analysis) — Feb 21, 2025 resolution; 503A/503B compounding wind-down; litigation posture
- Novo Nordisk Form 20-F (SEC EDGAR) — Issuer disclosure of US semaglutide exclusivity and ANDA settlements
- CNBC — India generic semaglutide launch — India generic entry and pricing after March 2026 expiry
Discuss a Similar Matter
Planning a follow-on entry? We map the cliffs, chart the live claims and hand engineering the design-around brief.
Discuss a Similar Matter
Frequently Asked Questions
What is a GLP-1 biosimilar freedom to operate analysis?
It is a claim-level review of the patents live in each target market for a GLP-1 product, mapped against the developer’s specific formulation and device, to determine where and when they can launch without infringing — and which claims a design-around must clear.
Why sequence a launch across markets instead of a single date?
Because the semaglutide patent cliff falls at different times by country — 2026 in Canada, India and Brazil, but around 2032 in the US — and each market carries its own surviving formulation and device claims. A single date would either forfeit early markets or invite US litigation.
Does a compound-patent expiry mean the market is open?
No. Formulation, oral-dosing and injection-device patents survive the compound patent and must be cleared or designed around. In this scenario those secondary claims, not the molecule, were the real gate in the near-term markets.
Is this a real client engagement?
This is a representative scenario built from PerspireIP’s freedom-to-operate method and publicly verifiable facts about the GLP-1 patent landscape. The figures are illustrative of the approach, not the results of a named engagement.